Suzhou Kintor Pharmaceutical Inc,

2 in Phase 3

Quick facts

Phase 3 pipeline

KX-826-（5%） BID · Dermatology
KX-826 is a topical androgen receptor antagonist that inhibits DHT-mediated signaling in hair follicles to treat androgenetic alopecia.
Proxalutamide (GT0918) · Oncology
Proxalutamide is an androgen receptor antagonist.

Phase 2 pipeline

GT20029 Tincture
GT90001
KX-826 0.5% BID
KX-826 1.0% BID

Phase 1 pipeline

GT20029 Gel
GT90001 and Nivolumab
KX0826

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Suzhou Kintor Pharmaceutical Inc, portfolio CI brief
Suzhou Kintor Pharmaceutical Inc, pipeline updates RSS

Frequently asked questions about Suzhou Kintor Pharmaceutical Inc,

What is Suzhou Kintor Pharmaceutical Inc,'s pipeline?

Suzhou Kintor Pharmaceutical Inc, has 2 drugs in Phase 3, 4 in Phase 2, 3 in Phase 1. Late-stage candidates include KX-826-（5%） BID, Proxalutamide (GT0918).

Sector hub: All tracked pharma companies